INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 130 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 2.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $551 | +8.7% | 41,037 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $507 | -99.9% | 41,037 | -28.3% | 0.00% | 0.0% |
| Q3 2022 | $797,000 | +169.3% | 57,195 | +166.7% | 0.00% | – |
| Q2 2022 | $296,000 | -70.5% | 21,442 | -65.2% | 0.00% | -100.0% |
| Q1 2022 | $1,002,000 | +45.0% | 61,615 | +45.2% | 0.00% | 0.0% |
| Q4 2021 | $691,000 | +265.6% | 42,421 | +454.3% | 0.00% | – |
| Q4 2020 | $189,000 | +626.9% | 7,653 | +1079.2% | 0.00% | – |
| Q3 2020 | $26,000 | -92.0% | 649 | -90.4% | 0.00% | – |
| Q2 2020 | $325,000 | +282.4% | 6,795 | +401.1% | 0.00% | – |
| Q1 2020 | $85,000 | – | 1,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |